Literature DB >> 16487684

Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells.

Guillaume Dalmasso1, Agnès Loubat, Stéphanie Dahan, Gustavo Calle, Patrick Rampal, Dorota Czerucka.   

Abstract

Induction of apoptosis and necrosis by enterohemorrhagic Escherichia coli (EHEC) has been reported in vivo and in vitro, but features of cell death were not noted in those reports. Since tumor necrosis factor-alpha (TNF-alpha) has been implicated in the apoptosis of invasive bacteria, we investigated the role of this cytokine in EHEC-induced apoptosis. We hypothesize that the probiotic yeast strain Saccharomyces boulardii that interferes with EHEC-induced pro-inflammatory pathways delays EHEC-induced apoptosis. By 6 h of infection, flow cytometry analysis of T84 cells demonstrated that 40% of cells were FITC-annexin-V-positive and 40% of cells incorporated both annexin and propidium iodide (PI). Simultaneously, western blot analysis demonstrated that procaspases-8 and -3 were cleaved. Fragmentation of internucleosomal DNA revealed evidence of apoptotic leader formation after 8 and 9 h of infection. Procaspase-9 activation and 3',3-dihexyloxacarbocyanine iodide (DiOC(6)) incorporation were observed at 3 h of infection. In cells preincubated with S. boulardii and infected with EHEC in the presence of yeast, the quantities of procaspases-8, -9 and -3 did not vary, and no DNA fragmentation was observed. The TNF-alpha transcript level and the level of secreted TNF-alpha increased considerably (P<0.001vs control cells) at 6 h of infection in EHEC-alone-infected cells, but were significantly reduced in cells infected in the presence of S. boulardii (P<0.001vs EHEC-alone-infected cells). The presence of anti-TNF-alpha antibody during infection reduced by 30% the level of FITC-annexin V-positive cells. Altogether, these findings demonstrated that: (i) EHEC infection stimulated TNF-alpha synthesis that is implicated in apoptosis of T84 cells; and (ii) S. boulardii induced a decrease in TNF-alpha and related apoptosis in EHEC-infected T84 cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487684     DOI: 10.1016/j.resmic.2005.11.007

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  19 in total

Review 1.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

2.  Human intestinal epithelial cell-derived molecule(s) increase enterohemorrhagic Escherichia coli virulence.

Authors:  Tarun Bansal; Dae N Kim; Tim Slininger; Thomas K Wood; Arul Jayaraman
Journal:  FEMS Immunol Med Microbiol       Date:  2012-12

Review 3.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

4.  Enterohemorrhagic Escherichia coli O157:H7 survival in an in vitro model of the human large intestine and interactions with probiotic yeasts and resident microbiota.

Authors:  Jonathan Thévenot; Lucie Etienne-Mesmin; Sylvain Denis; Sandrine Chalancon; Monique Alric; Valérie Livrelli; Stéphanie Blanquet-Diot
Journal:  Appl Environ Microbiol       Date:  2012-11-30       Impact factor: 4.792

5.  The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.

Authors:  Atakan Sezer; Ufuk Usta; Irfan Cicin
Journal:  Med Oncol       Date:  2008-12-09       Impact factor: 3.064

6.  Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation.

Authors:  S Thomas; I Przesdzing; D Metzke; J Schmitz; A Radbruch; D C Baumgart
Journal:  Clin Exp Immunol       Date:  2009-01-21       Impact factor: 4.330

7.  Saccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation state.

Authors:  Alexandra Canonici; Emilie Pellegrino; Carole Siret; Chloé Terciolo; Dorota Czerucka; Sonia Bastonero; Jacques Marvaldi; Dominique Lombardo; Véronique Rigot; Frédéric André
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

8.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Authors:  Theodoros Kelesidis; Charalabos Pothoulakis
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.802

9.  Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications.

Authors:  Rima Hatoum; Steve Labrie; Ismail Fliss
Journal:  Front Microbiol       Date:  2012-12-19       Impact factor: 5.640

Review 10.  Role of endogenous microbiota, probiotics and their biological products in human health.

Authors:  Gordon S Howarth; Hanru Wang
Journal:  Nutrients       Date:  2013-01-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.